Finance Watch: Scorpion Closes $162m Series B, Bringing Recent Total To $270m
$1.67bn In New VC Deals Includes Nearly $1bn In Two Days
Executive Summary
Private Company Edition: The pre-J.P. Morgan Healthcare Conference financing news deluge during the first week of 2021 included several significant venture capital deals, including a $226m series B round for Affinivax, Ikena’s $120m series B round and an $88m series A round for Aro.
You may also be interested in...
Finance Watch: Roivant To Go Public In SPAC Merger, Raise $611m
Public Company Edition: Roivant’s deal sets its market cap at $7.3bn. Beyond the Werewolf and Vaccitech offerings, more drug developers are slated to go public during the first week of May. And in follow-on offerings, COMPASS Pathways raises $144m and Aldeyra brings in $125m.
Finance Watch: Two SPAC Deals, Two IPOs Take Four Biopharmas Public
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
IPO Update: What A Difference A (Pandemic) Year Makes
Just nine drug developers went public in the US during the first quarter of last year, but with the industry boosted by pandemic response, 32 biopharma companies launched IPOs in Q1 of this year.